30,227 Shares in IQVIA Holdings Inc. $IQV Purchased by OP Asset Management Ltd

OP Asset Management Ltd acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 30,227 shares of the medical research company’s stock, valued at approximately $5,155,000.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the last quarter. Empowered Funds LLC raised its holdings in IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after acquiring an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the 2nd quarter valued at approximately $514,000. First Trust Advisors LP boosted its stake in IQVIA by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. HSBC set a $210.00 target price on IQVIA in a research report on Wednesday, June 3rd. Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Price Performance

NYSE IQV opened at $191.12 on Friday. The company has a 50-day moving average price of $174.43 and a 200-day moving average price of $190.07. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $31.90 billion, a P/E ratio of 23.68, a PEG ratio of 1.60 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the firm posted $2.70 earnings per share. The firm’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.